Hema.to funding news – Munich-based Hema.to Raises €3.6M in Fresh Funding

Monika Steger, Managing Director of Bayern Kapital, adds, “The workload and pressure in clinical laboratories are high and for life-threatening diseases such as leukaemia or lymphoma, early and accurate diagnosis can make the difference between negative disease progression and life-saving, early intervention. With Hema.to’s AI-supported analysis platform, the time taken to analyse blood data can be reduced to a fraction of the usual manual time. In this way, the company not only relieves the burden on clinical laboratories and promotes patient well-being, but also addresses a global market with a volume of several billion dollars. We therefore see great potential in Hema.to’s solution – both in Europe, where it is already being used in various laboratories and internationally.”

Bayern Kapital is a venture capital firm based in Bavaria, managing €700M and investing up to €25M per company. With over 30 years of experience and more than 110 active companies in its portfolio, it is one of the top investors in the DACH region. Since 1995, it has invested over €500M in over 320 startups.

Hema.to will use the funding to improve its blood cancer diagnostics, get more certifications in Europe, run clinical studies, expand into immune disorder diagnostics, and grow its business.

Karsten Miermans, Hema.to’s CEO and co-founder, says, “At Hema.to, we like to say that we want to ‘make your blood speak’. Every 3rd person suffers from a life-altering immune disease at some point in their life. Blood data holds the key to the immune system, but at present life-threatening illnesses like leukaemia or lymphoma, can be overlooked in blood analysis—even when the data that indicates otherwise is right there. Through the AI models on our platform, we pull this data to the surface to get every patient an accurate diagnosis and treatment as early as possible. This is how we save lives.”

With more samples to process and not enough staff in Europe's busiest clinical labs, cytometry teams are facing longer processing times and a higher chance of missed diagnoses. Hema.to’s AI-powered technology cuts analysis time from 20 minutes to just one minute, improving the detection of leukaemia and lymphoma while reducing false negatives.

Read also - Fund F funding news – Vienna-based Fund F Closes First Fund at €28Million

Hema.to is a deep-tech AI company that creates cloud-based software for early and accurate diagnosis of blood cancers and immune diseases. Their goal is to support personalized treatment based on each patient’s immune profile.

About Hema.to

Hema.to is dedicated to improving cytometry and making a big impact on immune medicine. They aim to ensure every patient receives the right treatment at the right time for their unique immune system.